MicroRNA‐129‐1‐3p Represses the Progression of Triple‐Negative Breast Cancer by Targeting the GRIN2D Gene

Li, Qi; Gu, Zhengtao; Tan, Qi; Ren, Liqun; Suxian, Chen

doi:10.1155/2022/1549357

Cited by 7 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that miR-129-1-3p may inhibit the migration of the human gastric cancer cell line BGC-823 by targeting and regulating bradykinin receptor B2 (BDKRB2), thereby inhibiting the metastasis of gastric cancer ( Wang et al, 2014 ). MiR-129-1-3p has also been reported to play a role in triple-negative breast cancer by targeting GRIN2D and inhibiting tumor cell growth ( Li et al, 2022 ). However, the pathogenesis of miR-129-1-3p in prostate cancer has not been studied so far.…”

Section: Discussionmentioning

confidence: 99%

A panel based on three-miRNAs as diagnostic biomarker for prostate cancer

Chen,

Lu,

Lin

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is one of the most prevalent malignancies affecting the male life cycle. The incidence and mortality of prostate cancer are also increasing every year. Detection of MicroRNA expression in serum to diagnose prostate cancer and determine prognosis is a very promising non-invasive modality.Materials and method: A total of 224 study participants were included in our study, including 112 prostate cancer patients and 112 healthy adults. The experiment consisted of three main phases, namely, the screening phase, the testing phase, and the validation phase. The expression levels of serum miRNAs in patients and healthy adults were detected using quantitative reverse transcription-polymerase chain reaction. Receiver operating characteristic (ROC) curves and the area under the curve (AUC) were used to evaluate the diagnostic ability, specificity, and sensitivity of the candidate miRNAs.Result: Eventually, three miRNAs most relevant to prostate cancer diagnosis were selected, namely, miR-106b-5p, miR-129-1-3p and miR-381-3p. We used these three miRNAs to construct a diagnostic panel with very high diagnostic potential for prostate cancer, which had an AUC of 0.912 [95% confidence interval (CI): 0.858 to 0.950; p < 0.001; sensitivity = 91.67%; specificity = 79.76%]. In addition, the three target genes (DTNA, GJB1, and TRPC4) we searched for are also expected to be used for prostate cancer diagnosis and treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

A panel based on three-miRNAs as diagnostic biomarker for prostate cancer

Chen,

Lu,

Lin

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…In triple-negative breast cancer (TNBC), the role of microRNA (miRNA) in the regulation of NMDAR has been reported. The transfection of MDA-MB-231 cells with miR-129-1-3p suppressed tumor growth, and reduced cell proliferation ( 105 ). The increase in Ca 2+ is considered to be central in the progression of breast cancer, and the miR-129-1-3p transfection of MDA-MB-231cells was followed by the decrease in intracellular Ca 2+ and the activation of GRIN2D (Glutamate Ionotropic Receptor NMDA Type Subunit 2D), indicating that the miR-129-1-3p can suppress the development of TNBC by the regulation of MNDAR ( 105 ).…”

Section: Role Of Glutamate Receptors In Cancermentioning

confidence: 99%

“…Moreover, the expression of other iGluRs such as AMPAR and KA can be detected to exclude their effect in the inhibitory effect of miR-129-1-3p. Although miRNAs can regulate different aspects of cancer biology, including angiogenesis, drug resistance, apoptosis, proliferation, invasion, and metastasis ( 105 ), acting as tumor suppressors in several types of cancer a lot needs to be done to link the beneficial effect of miRNA with iGluRs in different types of cancer.…”

Section: Role Of Glutamate Receptors In Cancermentioning

confidence: 99%

The role of glutamate receptors in the regulation of the tumor microenvironment

Koda

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Glutamate, as one of the most important carbon sources in the TCA cycle, is central in metabolic processes that will subsequently influence tumor progression. Several factors can affect the expression of glutamate receptors, playing either a tumor-promoting or tumor-suppressor role in cancer. Thus, the activation of glutamate receptors by the ligand could play a role in tumor development as ample studies have demonstrated the expression of glutamate receptors in a broad range of tumor cells. Glutamate and its receptors are involved in the regulation of different immune cells’ development and function, as suggested by the receptor expression in immune cells. The activation of glutamate receptors can enhance the effectiveness of the effector’s T cells, or decrease the cytokine production in immunosuppressive myeloid-derived suppressor cells, increasing the antitumor immune response. These receptors are essential for the interaction between tumor and immune cells within the tumor microenvironment (TME) and the regulation of antitumor immune responses. Although the role of glutamate in the TCA cycle has been well studied, few studies have deeply investigated the role of glutamate receptors in the regulation of cancer and immune cells within the TME. Here, by a systematic review of the available data, we will critically assess the physiopathological relevance of glutamate receptors in the regulation of cancer and immune cells in the TME and provide some unifying hypotheses for futures research on the role of glutamate receptors in the immune modulation of the tumor.

show abstract

“…Studies have shown that miRNAs play an important role in attenuating cardiotoxicity 19 . Studies have shown that miR‐129‐1‐3p can attenuate THP‐induced cardiotoxicity and inhibit the development and progression of triple‐negative breast cancer by regulating the calcium pathway 20,21 …”

Section: Introductionmentioning

confidence: 99%

“…19 Studies have shown that miR-129-1-3p can attenuate THP-induced cardiotoxicity and inhibit the development and progression of triple-negative breast cancer by regulating the calcium pathway. 20,21 lncRNA Miat plays an important role in the occurrence and development of tumors, however, its role in THP-induced cardiotoxicity remains unclear. Therefore, this study investigated the role and potential mechanism of Miat in protecting against THP-induced cardiotoxicity.…”

mentioning

confidence: 99%

LncRNA Miat knockdown protects against pirarubicin‐induced cardiotoxicity by targeting miRNA‐129‐1‐3p

Huang

Zhang

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

Pirarubicin (THP) is a widely used antitumor drug in clinical practice, but its cardiotoxicity limits its use. The aim of this study was to investigate the protective effect and mechanism of knockdown of lncRNA Miat in THP‐induced cardiotoxicity. The extent of damage to immortalized cardiomyocytes in mice was assessed by CCK8, TUNEL, ROS, Ca2+, RT‐qPCR, and Western blot. The relative levels of Miat in THP‐treated cardiomyocytes (HL‐1) were measured. The protective effect of Miat on THP‐treated HL‐1 was assessed. The binding relationship between lncRNA Miat and mmu‐miRNA‐129‐1‐3p was verified by a dual luciferase reporter gene assay. The protective role of Miat/miRNA‐129‐1‐3p in THP‐induced HL‐1 was explored by performing a rescue assay. THP reduced cell viability, induced apoptosis, triggered oxidative stress and calcium overload. Expression of Miat in HL‐1 was significantly elevated after THP treatment. Miat knockdown significantly alleviated the cardiotoxicity of THP. MiR‐129‐1‐3p is a direct target of Miat. Knockdown of miR‐129‐1‐3p reversed the protective effect of Miat knockdown on HL‐1. Miat knockdown can alleviate THP‐induced cardiomyocyte injury by regulating miR‐129‐1‐3p.

show abstract

MicroRNA‐129‐1‐3p Represses the Progression of Triple‐Negative Breast Cancer by Targeting the GRIN2D Gene

Cited by 7 publications

References 31 publications

A panel based on three-miRNAs as diagnostic biomarker for prostate cancer

A panel based on three-miRNAs as diagnostic biomarker for prostate cancer

The role of glutamate receptors in the regulation of the tumor microenvironment

LncRNA Miat knockdown protects against pirarubicin‐induced cardiotoxicity by targeting miRNA‐129‐1‐3p

Contact Info

Product

Resources

About